-
One more acquisition in the news, and a fairly large announcement at that. Just one more indication of the interest and investments from Pharma expanding beyond just drugs and pursuing biotech companies with state of the art technologies for healthcare, this one in the surgical products area. ...
-
This was somewhat of a first for the US FDA to trust Chinese data. Shenzhen Chipscreen Bio sciences Ltd. was also awarded the Most Valued Partner for Roche R&D Center. Oncology drugs are one of their primary focuses, with individuals trained here in the US and returning to China to create their...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-15-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Pharma, Biotech, FDA, Oncology, R and D, China pharma, Chipscreen, biosciences, HUYA
-
The bar has also risen on Venture Capital money and is harder to get, and so much of the research is still in the “Science” stage, there have been a few companies that have had failed products and just folded up and went away. This certainly leaves the door open for Pharma, who has the financials...
-
It is here but evolving slower than what all of us might like to see, and in many areas it is still so much of a “Science” but as developments occur through biotech we are seeing some amazing results. There’s also the bridging of the gap with bringing genomics to the point of care, as physicians...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-26-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, healthcare, Pharma, Biotech, Cancer, tumors, Genentech, Herceptin, cancer vaccine
-
Recently announced is the project to begin at Scripps in San Diego as related news, coupled with the announcement of the new sequencing service that will be able to offer a complete sequence at a wholesale price may have held a bit of inspiration here for Navigenics to enter the full sequencing market...
-
This is not welcome news by any means for the VC money that was invested. A redirection of the product was too costly as well, thus they shop closes with million invested and a loss. The FDA restrictions also played a role in the limiting of consumer clinical trials here, so with a series...
-
The group has grown in 7 years from five people focused on healthcare worldwide at Microsoft; now there are more than 700. This group is for responsible primarily for the enterprise space (in biopharma and medical devices), so these are the largest customers in the U.S. I have provided a...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-09-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, Microsoft/Windows News, personalized medicine, Genomics, healthcare, microsoft, Medical Records, Biotech, R and D, Server 2008, Life Sciences, SharePoint, Windows Presentation Foundation, HPC Server 2008
-
Not only do we see venture capital money here, also some big Pharma names. In a related story, Roche sees diagnostic machines and test kits as crucial to assessing and treating disease in the future and their risk profile has recognition of being one large investor in a growing area of drug research...
-
How hot is genomics today? There are several manufacturers of the machines that will accomplish running our DNA, our complete DNA. I know to the average person this gets a little confusing, but the companies listed here are the companies that manufacture the machines that do the entire work...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-25-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, Other Items of Interest, My Commentaries, personalized medicine, Genomics, Biotech, Pharmacogenomics, DNA Testing, Helicos, Sequencing, RNA
-
He also did recognize the effect of current budget cuts are having on the progression of R and D, as anyone who applies for and receives grants these days knows the bar has been raised and it is a bit more difficult to secure them, as a result many are looking to investors outside the NIH for funding...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-24-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, Genomics, healthcare, Biotech, Grants, Budgets, R and D, NIH, National Institue of Health
-
I think many might agree here, as Intellectual Property is getting pretty gray these days. Software companies seem to have a better handle on this, but they even face challenges too. Once you share intellectual property, the cat's out of the bag per se. Add on some economic constraints...
-
Many of the generic manufacturers started years back with knock off drugs to sell locally in India, but now the game is changing to where US Pharma is using some of the talent, which costs less than R and D individuals here in the states, to further develop existing work, in other words somewhat continue...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-05-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Biotech, Cancer, FDA, Budgets, R and D, Alzheimers, Outsourcing
-
All over healthcare the big fish, little fish story is either taking place or actions are in the making for offers. There certainly are a number of big Pharma companies with money to foot the bill, that is if the Biotech companies see it fit to consider the options. One problem as indicated in...
-
More additional affiliations for the FDA to gather information. In the news recently have been other agreements with companies such as Blue Cross and others who will be providing data to also study the effects of drugs through medical record information in their files, based on claims, etc. No...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
08-18-2008
Filed under:
Filed under: Medically Related, Technology, Insurance, Pharma/FDA News, health insurance, healthcare IT, Pharma, Biotech, FDA, Medco, Pharmacogonomics
-
Patrice Milos, Vice President and Chief Scientific Officer, Helicos Biosciences This week I had the opportunity to talk with Patrice Milos from Helicos Biosciences who has a long background in global research and spent a number of years at Pfizer as Executive Director at Pfizer Global Research and Development...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
08-15-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, Other Items of Interest, My Commentaries, personalized medicine, healthcare, Electronic Medical Records, Biotech, cancer research, Research, Gene Sequencing, Disease, DNA Testing, Phamaceuticals, Helios